One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v130.suppl_1.3482.3482
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Jun 25, 2021 |
Affiliation: Essen University Hospital, Alexion Pharmaceuticals (United States), Leeds Teaching Hospitals NHS Trust, Yonsei University, Severance Hospital, University of Duisburg-Essen, Hôpital Claude Huriez, Sunnybrook Health Science Centre, Health Sciences Centre, Samsung (South Korea), Royal Melbourne Hospital, Seoul St. Mary's Hospital
Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
